Cascadian Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in developing innovative therapeutic product candidates for the treatment of cancer. Our goal is to discover, develop and commercialize novel compounds that have the potential to improve the lives and outcomes of cancer patients. Our most advanced product candidate is ONT-380, an orally active and selective small molecule HER2 inhibitor. We are headquartered in Seattle, Washington. For more information, visit www.cascadianrx.com.
View Top Employees from Cascadian Therapeutics, Inc.Website | http://www.cascadianrx.com |
Ticker | NASDAQ:CASC |
Revenue | $1 million |
Funding | $84.4 million |
Employees | 13 (4 on RocketReach) |
Founded | 1985 |
Address | 2601 Fourth Avenue Suite 500, Seattle, Washington 98121, US |
Phone | (206) 801-2100 |
Fax | (206) 801-2101 |
Technologies |
JavaScript,
HTML,
Twitter
+21 more
(view full list)
|
Industry | Biotechnology, Business Services, Pharmaceuticals, Science and Engineering, Healthcare, Health Care, Drug Manufacturing & Research, Education, Therapeutics, Organizations, Medical Testing & Clinical Laboratories |
Competitors | Clovis Oncology, EnGeneIC, Endocyte, Immunocore, Morphotek, Inc. |
SIC | SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 325 Companies, NAICS Code 3254 Companies, NAICS Code 54 Companies, NAICS Code 5417 Companies, NAICS Code 32 Companies, NAICS Code 32541 Companies, NAICS Code 541 Companies |
Looking for a particular Cascadian Therapeutics, Inc. employee's phone or email?
The Cascadian Therapeutics, Inc. annual revenue was $1 million in 2024.
4 people are employed at Cascadian Therapeutics, Inc..
Cascadian Therapeutics, Inc. is based in Seattle, Washington.
The NAICS codes for Cascadian Therapeutics, Inc. are [325, 3254, 54, 5417, 32, 32541, 541].
The SIC codes for Cascadian Therapeutics, Inc. are [283, 28].